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Abstract
In 2012 a novel coronavirus, MERS-CoV, associated with severe respiratory disease emerged in the Arabian
Peninsula. To date, 55 human cases have been reported, including 31 fatal cases. Several of the cases were likely a
result of human-to-human transmission. The emergence of this novel coronavirus prompts the need for a small
animal model to study the pathogenesis of this virus and to test the efficacy of potential intervention strategies. In this
study we explored the use of Syrian hamsters as a small animal disease model, using intratracheal inoculation and
inoculation via aerosol. Clinical signs of disease, virus replication, histological lesions, cytokine upregulation nor
seroconversion were observed in any of the inoculated animals, indicating that MERS-CoV does not replicate in
Syrian hamsters.
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Introduction
In June of 2012, a novel coronavirus, designated Middle East
respiratory syndrome coronavirus (MERS-CoV) [1] and
classified as a 2c betacoronavirus [2,3], was isolated from a
patient with a fatal case of pneumonia and renal failure in
Saudi Arabia [3]. To date, 55 human cases of MERS-CoV have
been reported with 31 fatalities [4], including two fatal cases in
Jordan in April of 2012 that were retrospectively detected. A
cluster of cases in the UK in February of 2013 suggested
human-to-human transmission in two cases with no travel
history to the Middle East [4].
Several 2c betacoronaviruses with high sequence identity to
MERS-CoV have been detected in bats in Europe, Ghana and
Mexico [5,6] suggesting that bats are the natural reservoir of
MERS-CoV. It is currently unclear whether human cases were
a result of direct zoonotic transmission from this reservoir to
humans or whether an intermediate host was involved. In vitro
data suggest that MERS-CoV has a broad host range [7],
increasing the likelihood that an intermediate host was involved
in amplifying or transmitting the virus from its natural reservoir
to humans.
In 2003 another betacoronavirus, SARS-CoV, caused a
pandemic with approximately 8000 human cases and a case
fatality rate of ~10% [8]. The emergence of MERS-CoV with a
high case fatality rate and the potential to transmit between
humans stresses the need for a small animal model to study
the pathogenesis of this virus and to test the efficacy of
potential therapeutic or prophylactic intervention strategies. In
Syrian hamsters, SARS-CoV replicates extensively in the
respiratory tract in the first week after intranasal inoculation
with 103 TCID50 [9] and, depending on the SARS-CoV strain
used, can cause mortality in a small subset of infected animals
[10]. In the present study, we explored the suitability of the
Syrian hamster as a small animal model for MERS-CoV isolate
HCoV-EMC/2012 infection or disease.
Materials and Methods
Ethics Statement. All animal experiments were approved by
the Institutional Animal Care and Use Committee of the Rocky
Mountain Laboratories, and performed following the guidelines
of the Association for Assessment and Accreditation of
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Laboratory Animal Care, International (AAALAC) by certified
staff in an AAALAC-approved facility.
The work with infectious MERS-CoV was approved under
BSL3 conditions by the Institutional Biosafety Committee (IBC).
Sample inactivation was performed according to standard
operating procedures approved by the IBC for removal of
specimens from high containment.
Virus and cells. MERS-CoV isolate HCoV-EMC/2012 was
propagated in VeroE6 cells in Dulbecco’s Modified Eagle
Medium (DMEM; Sigma) supplemented with 2% fetal calf
serum (Logan), 1 mM L-glutamine (Lonza), 50 U/ml penicillin
and 50 µg/ml streptomycin (Gibco). The HCoV-EMC/2012 virus
stock was titrated by end-point titration in VeroE6 cells. VeroE6
cells were inoculated with tenfold serial dilutions of virus stock
in DMEM supplemented with 2% fetal calf serum, 1 mM L-
glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin. Five
days after inoculation, cytopathic effect (CPE) was scored and
the TCID50 was calculated from 10 replicates by the method of
Spearman-Karber.
Animal experiments. Three groups of 40 hamsters were
inoculated with MERS-CoV isolate HCoV-EMC/2012; one
group received 4x102 TCID50 via aerosols (see below), one
group received 103 TCID50 intratracheally in a total volume of
300 µl, and one group received 106 TCID50 intratracheally in a
total volume of 300 µl. Mock infected hamsters (four animals
per time point) inoculated with DMEM intratracheally or via
aerosols were included as controls for histopathology and
cytokine analysis. Eight hamsters in each group and eight
control hamsters (4 intratracheal and 4 aerosol) were injected
with an IPTT-300 temperature transponder (BMDS) to monitor
body temperature daily. Animals were weighed daily and
observed for signs of disease. Nasal, oropharyngeal, urogenital
and rectal swabs were obtained on 1, 2, 3, 4, 5, 6, 7, 9 and 11
days post inoculation (dpi) and analyzed for the presence of
viral RNA. On 2, 4, 8, 14 and 21 dpi, eight hamsters in each
group were euthanized and trachea, heart, lung, spleen, liver,
kidney, ileum, colon, bladder, nasal turbinates and brain were
collected for virological and histopathological analysis.
Aerosol challenge. Hamsters were exposed to MERS-CoV
isolate HCoV-EMC/2012 using a 38 liter, whole body exposure
chamber within a Class II biological safety cabinet inside high
containment. The animals received a single, 10 minute aerosol
exposure and were contained using stainless steel, wire mesh
cages (2 hamsters/cage). Anesthesia was not administered to
the animals. The aerosol challenge consisted of 5 runs with
each run containing 4 wire mesh cages. Viral inoculum and
collection material were prepared the day of the exposure
using DMEM and 1% fetal calf serum. Aerosol particles were
generated by a 3-jet Collison nebulizer (BGI Inc., MA, USA)
operating at 7.5 lpm (25-30 PSI) and ranged from 1–3 µm in
size. The contents of the aerosol exposure were collected in an
All Glass Impinger (AGI, Ace Glass Inc., NJ, USA) continuously
operating at 6.0 lpm. Both generator and sampler were flow
checked using a frictionless bubble meter (Gilibrator,
Sensidyne LP, FL, USA) to ensure the desired flow rates and
pressure were achieved. In between aerosol runs a period of 5
minutes allowed the particles from the previous run to settle.
The exposure chamber maintained negative pressure
throughout the duration of the inoculation. An aerosol
management platform (AeroMP, Biaera Technologies, USA)
was used to conduct the exposures. The automated aerosol
system controls, monitors, and maintains several parameters
that impact aerosol studies [11]. Respiratory minute volume
rates were determined using a formula derived by Alexander et
al [12]. Weights were averaged for aerosol exposure group/run
(n=8, n=40 total). A presented dose was calculated using the
simplified formula D = R x Caero x Texp [11], where D is the
presented or inhaled dose (expressed in TCID50), R is the
respiratory minute volume (L/min), Caero is the aerosol
concentration (TCID50/L), and Texp is duration of the exposure
(min).
Histopathology. Histopathology was performed on select
hamster tissues. After fixation for 7 days in 10% neutral-
buffered formalin and embedding in paraffin, tissue sections
were stained with hematoxylin and eosin (H&E). For the
histopathological analysis of the nasal turbinates whole
hamster skulls were used. The skulls were decalcified using a
20% EDTA solution in sucrose (Newcomer Supply) and
allowed to sit at room temperature for 3 weeks. The 20%
EDTA/sucrose solution was changed once prior to mid-sagittal
sectioning of the skull.
Immunohistochemistry. Immunohistochemistry was
performed on lungs, kidney, small intestine, urinary bladder
and colon of normal hamsters using an α-DPP4 antibody (α-
CD26; 1:800; Abcam). The tissues were processed for
immunohistochemistry using the Discovery XT automated
processor (Ventana Medical Systems) with a DapMap kit
(Ventana Medical Systems).
RNA extraction. RNA was extracted from swab samples
using the NucleoSpin 96 Virus Core kit (Macherey-Nagel) and
a Corbett Robotics model CAS 1820 automatic RNA extractor.
RNA was eluted in 100 µl. RNA was extracted from whole
blood using the QiaAmp Viral RNA kit (Qiagen) according to
the manufacturer’s instructions. RNA was eluted in 60 µl.
Tissues (30 mg) were homogenized in RLT buffer and RNA
was extracted using the RNeasy kit (Qiagen). RNA was eluted
in 50 µl.
Quantitative PCR. For detection of viral RNA, 5 µl RNA was
used in a one-step real-time RT-PCR upE assay [13] using the
Rotor-GeneTM probe kit (Qiagen) according to instructions from
the manufacturer. In each run, standard dilutions of a titered
virus stock were run in parallel, to calculate TCID50 equivalents
in the samples. Hamster Mx2 gene expression was determined
as described previously [14]. qRT-PCR was performed as
described above using Mx2 specific primers. The fold-change
of each gene was calculated by normalizing the change in CT
(ΔCT) to the CT values for RPL18 as an internal reference gene
for each sample and comparing this to the CT values of mock
inoculated hamsters (2-ΔΔCT).
ELISA. Immuno-globulin G antibody responses were
measured in an enzyme-linked immunosorbent assay (ELISA)
using MERS-CoV isolate HCoV-EMC/2012. HCoV-EMC/2012
containing cell culture supernatant was concentrated and
purified by spinning two hours at 21000 rpm over a 15%
OptiPrep (Axis-Shield) cushion. The pellet was resuspended in
PBS and triton X-100 was added to a final concentration of 1%
and the suspension was then gamma-irradiated before removal
from high containment. This suspension was then used to coat
MERS-COV Inoculation of Syrian Hamsters
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immuno 96 microwell maxisorp plates (NUNC) at 4°C
overnight. Subsequently, plates were blocked with 5% skim
milk in PBS containing 0.05% Tween 20 (PBST) for 1.5 hours
at 4°C. After 3 washes with PBST, 50 µl of diluted serum
samples were added, and the plates were incubated for 1 hour
at 37°C. Bound antibodies were detected after 3 washes using
an anti-hamster secondary antibody conjugated with
horseradish peroxidase (HRP; KPL). Following incubation for 1
hour at 37°C, bound HRP was detected using the ABTS®
Peroxidase Substrate System (KPL). The absorbance at 405
nm was measured using a microplate spectrophotometer. Sera
were considered positive when absorbance was higher than
three standard deviations above the mean of negative control
sera. Sera obtained from rabbits immunized with HCoV-EMC/
2012 were used as a positive control.
Results & Discussion
Hamsters were divided into 3 groups of 40 hamsters. The
first group was inoculated intratracheally with 103 TCID50 of
MERS-CoV isolate HCoV-EMC/2012; the second group was
inoculated intratracheally with 106 TCID50 of HCoV-EMC/2012
and the third group was inoculated with 4x102 TCID50 HCoV-
EMC/2012 via aerosolization. Hamsters were observed for
clinical signs of disease daily for 21 dpi and body weight and
body temperature were measured. None of the hamsters in the
three inoculated groups showed signs of disease, weight loss
or increased body temperature (Figure 1). Nasal,
oropharyngeal, urogenital and rectal swabs were obtained daily
between 1 and 11 dpi and were all negative by qRT-PCR.
Upon necropsy on 2, 4, 8, 14 and 21 dpi, no gross lesions were
observed. Lungs, spleen and mandibular lymph nodes
collected on 2, 4 and 8 dpi were analyzed for the presence of
HCoV-EMC/2012 vRNA by qRT-PCR and found to be
negative. Trachea, heart, lung, spleen, liver, kidney, ileum,
colon, urinary bladder, nasal turbinates and brain collected on
2, 4, 8, 14 and 21 dpi were used for histopathological analysis;
no lesions were observed that could be attributed to the virus in
any of the tissues examined (Figure 2).
Hamsters were mock inoculated (●), inoculated
intratracheally with 103 TCID50 HCoV-EMC/2012 (■), inoculated
intratracheally with 106 TCID50 HCoV-EMC/2012 (▲) or
inoculated with 4x102 TCID50 via aerosols (▼) and body weight
(A) and temperature (B) were measured. Average and
standard error of the mean are plotted for 8 animals per time
point.
Hamsters were mock inoculated (A and E), inoculated
intratracheally with 103 TCID50 HCoV-EMC/2012 (B and F),
inoculated intratracheally with 106 TCID50 HCoV-EMC/2012 (C
and G) or inoculated with 4x102 TCID50 via aerosols (D and H).
On 4 days post inoculation tissue sections of the lungs (A–D)
and kidneys (E–H) of these animals were collected and stained
with hematoxylin-eosin. The panels shown in this figure are
presentative for 4 animals analyzed per tissue per group.
Lungs, spleen and lymph nodes collected from the hamsters
intratracheally inoculated with 106 TCID50 and inoculated via
aerosols on 2, 4 and 8 dpi were also analyzed for upregulation
of the transcription of the Mx2 gene. Mx2 gene expression was
analyzed as an indicator of an innate immune response to virus
infection, since Mx2 is downstream of STAT1 and as such is an
indicator of a type I or type III IFN response (reviewed in 15. A
statistically significant upregulation of Mx2 gene expression
could not be detected in any of the hamsters, independent of
the inoculation route, inoculation dose or tissue analyzed
(Figure 3). Taken together these data indicate that the
hamsters were either not infected at all or the infection
occurred below the limit of detection of our assays. To
determine whether the animals were infected at all, we
developed an ELISA assay to detect antibodies against MERS-
CoV. Hamster sera collected on 21 dpi were analyzed for the
presence of antibodies; there was no evidence for
seroconversion in any of the inoculated animals, regardless of
inoculation route or dose. Thus, the MERS-CoV does not
replicate in Syrian hamsters and they are an unsuitable model
for studies into pathogenesis or potential prophylactic or
Figure 1.  Body weight and temperature in Syrian hamsters
inoculated with MERS-CoV isolate HCoV-EMC/2012.
doi: 10.1371/journal.pone.0069127.g001
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therapeutic intervention strategies. To determine whether the
recently described receptor for MERS-CoV, DPP4 [16], is
expressed in the Syrian hamster, we performed
immunohistochemistry on lung, kidney, small intestine, urinary
bladder and colon of normal hamsters using an α-DPP4
antibody. DPP4 could be detected in all tested hamster tissues
(Table 1) and was abundantly present in the lungs and kidneys
of Syrian hamsters (Figure 4). The abundant expression of
Figure 2.  Histological analysis of lungs and kidney of Syrian hamsters inoculated with MERS-CoV isolate HCoV-EMC/2012.
doi: 10.1371/journal.pone.0069127.g002
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DPP4 on bronchiolar epithelium and the occasional presence
on type I pneumocytes indicates that the absence of replication
in the Syrian hamster is not due to a lack of the receptor, but
rather to the fact that the epitope that MERS-CoV binds to is
not conserved in Syrian hamster DPP4 or that other restrictions
exist on the cellular level that prevent virus replication.
HCoV-EMC/2012. A qRT-PCR assay to detect Mx2 was
performed on RNA isolated from lungs, spleen and mandibular
lymph nodes collected on 2, 4 and 8 days post inoculation (dpi)
of Syrian hamsters with 106 TCID50 of HCoV-EMC/2012 (green
bars) via the intratracheal route (left panels) or 4x102 TCID50 of
HCoV-EMC/2012 via aerosol (right panels, green bars) and
compared to mock inoculated animals (blue bars). Data are
shown as the fold change of Mx2 over uninfected controls and
normalized to an internal reference gene (RPL18). Means were
calculated from 4 mock animals and 4 (2 dpi) or 8 (4 and 8 dpi)
inoculated animals. Error bars represent standard deviation.
Immunohistochemistry was performed on Syrian hamster
lung and kidney tissues using an α-DPP4 antibody. In the lung
(A and B), DPP4 was abundantly present on bronchiolar
epithelium (blue arrow) and smooth muscle cells (black arrows)
and was occasionally present on type I pneumocytes (black








epithelium +      
Type I pneumocyte +      
Nerve + + + + - +
Arteriolar smooth
muscle + + - - - -
Glomerular parietal
epithelium  +     
Lamina muscularis   +   -
Lamina propria
vessels   +   -
+. DPP4 detected; - DPP4 not detected. Open fields indicate the cell type is not
present in this tissue.
Figure 3.  Mx2 gene expression in hamsters after inoculation with MERS-CoV isolate
doi: 10.1371/journal.pone.0069127.g003
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arrowhead and inset in panel B). In the kidney, DPP4 was
present on glomerular parietal epithelium (white arrowhead)
and in nerve tissue (purple arrow).
Although these experiments did not result in a small animal
model for MERS-CoV, they do provide insight into the potential
host range of this virus.
Given the continuing circulation of the MERS-CoV virus and
the associated high case fatality rate, the search for an animal
infection/disease model is of utmost importance for our
understanding of the pathogenesis of this virus and for the
development of effective countermeasures.
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